VRCA
Verrica Pharmaceuticals Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Last price
4.82
▼ 0.04 (0.82%)
MARKET · —
Price
Open
4.98
Prev close
4.86
Day high
4.99
Day low
4.64
Volume
78.81K
Market cap
$82.80M
P/E (TTM)
—
52W range
3.28 – 9.82
Trailing performance
Returnvs SPY
1W
-3.02%
-1.7%
1M
-11.40%
-15.1%
3M
-18.31%
-21.4%
6M
-16.75%
-27.8%
YTD
-42.00%
-54.3%
1Y
-13.31%
-33.3%
3Y
-90.08%
-164.3%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$82.80M
Enterprise value$73.41M
Revenue (TTM)$30.32M
Gross profit$11.43M
EBITDA$-25.96M
Net income$-31.18M
EPS (TTM)$-1.74
Free cash flow$-9.04M
Total cash$11.20M
Total debt$1.81M
Book value / share$0.25
Shares outstanding17.18M
Float7.85M
Short % of float3.26%
Dividend yield—
Beta (5Y)1.49
Valuation & profitability ratios
Trailing P/E—
Forward P/E-3.27
PEG ratio—
Price / sales—
Price / book19.20
EV / revenue2.42
EV / EBITDA-2.83
Gross margin37.68%
Operating margin-194.46%
Profit margin-102.84%
Return on equity—
Return on assets-43.98%
Debt / equity42.03
Current ratio1.45
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | $35.58M | $7.57M | $5.12M | $9.03M |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | -$17.89M | -$76.58M | -$67.00M | -$24.49M |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | -$17.89M | -$76.58M | -$67.00M | -$24.49M |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.47 | -0.48 | -2.9% |
| Mar 2026 | -0.59 | — | — |
| Dec 2025 | -0.64 | -0.51 | +20.3% |
| Sep 2025 | -0.84 | 0.13 | +115.4% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.54 | 3 | $6.40M | -55.4% |
| Next quarter | -0.52 | 3 | $7.59M | +49.1% |
| Current year | -2.01 | 3 | $24.87M | -30.1% |
| Next year | -1.47 | 3 | $39.69M | +59.6% |
Analyst targets & ownership
Mean target$14.80
High target$20.00
Low target$10.00
Implied upside207.05%
Analyst count5
ConsensusNONE
Strong buy / Buy0 / 5
Hold1
Sell / Strong sell0 / 0
Held by insiders49.00%
Held by institutions27.14%
Institutions holding48
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
8.42M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 18, 26 | KIRBY JOHN J. Chief Financial Officer |
BUY | 5.00K | $24.65K | Direct |
| Aug 18, 26 | ROSENBERG NOAH L Officer |
BUY | 6.23K | $30.61K | Direct |
| Aug 17, 26 | RIEGER JAYSON Chief Executive Officer |
BUY | 25.00K | $125.75K | Direct |
| Aug 17, 26 | ZAWITZ DAVID Chief Operating Officer |
BUY | 6.00K | $29.88K | Direct |
| Dec 23, 25 | KIRBY JOHN J. Chief Financial Officer |
STOCK | 10.00K | $0 | Direct |
| Nov 25, 25 | RIEGER JAYSON Chief Executive Officer |
BUY | 94.31K | $400.11K | Direct |
| Nov 25, 25 | ZAWITZ DAVID Chief Operating Officer |
BUY | 10.00K | $42.42K | Direct |
| Nov 25, 25 | MANNING PAUL B. Director and Beneficial Owner of more than 10% of a Class of Security |
BUY | 4.13M | $17.51M | |
| Nov 25, 25 | KIRBY JOHN J. Chief Financial Officer |
BUY | 3.54K | $15.00K | Direct |
| Nov 25, 25 | ROSENBERG NOAH L Officer |
BUY | 2.36K | $10.00K | Direct |
| Mar 17, 25 | HAYES CHRISTOPHER G Officer |
SELL | 4.32K | $2.81K | Direct |
| Nov 26, 24 | MANNING PAUL B. Director and Beneficial Owner of more than 10% of a Class of Security |
STOCK | 450.00K | $0 | Direct |
| Nov 22, 24 | STALFORT JOHN A Director |
BUY | 1.12M | $1.12M | Direct |
| Nov 22, 24 | RIEGER JAYSON Chief Executive Officer |
BUY | 280.90K | $279.35K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BONACCORSO JOE |
Officer | 73.11K | Sale |
GOLDENBERG GARY |
Officer | 94.26K | Sale |
HAYES CHRISTOPHER G |
Officer | 176.46K | Sale |
KIRBY JOHN J. |
Chief Financial Officer | 23.96K | Purchase |
KOHLER TERRY |
Chief Financial Officer | 44.70K | Sale |
MANNING PAUL B. |
Director and Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
RIEGER JAYSON |
Chief Executive Officer | 208.30K | Purchase |
STALFORT JOHN A |
Director | 1.87M | Purchase |
WHITE TED W. |
Chief Executive Officer | 215.97K | Sale |
ZAWITZ DAVID |
Chief Operating Officer | 27.00K | Purchase |
Moving averages & technicals
SMA 10
4.95
-2.63% from price
SMA 20
5.13
-5.97% from price
SMA 50
5.60
-13.86% from price
SMA 100
5.94
-18.84% from price
SMA 200
6.18
-21.97% from price
EMA 12
4.99
-3.39% from price
EMA 26
5.21
-7.51% from price
EMA 50
5.48
-12.00% from price
RSI (14)
40.1
Neutral
MACD (12,26,9)
-0.22
Hist -0.01
ATR (14)
0.43
8.86% of price
Realised vol 30D
55.3%
Annualised
Bollinger upper
5.57
20, 2σ
Bollinger lower
4.68
20, 2σ
50 / 200 cross
Death
5.60 vs 6.18
Trend bias
Below 200
-21.97%
Risk profile
Beta vs SPY
1.97
More volatile than market
Correlation to SPY
0.27
Largely independent
Realised vol 30D
55.3%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-51.9%
Peak to trough
Max drawdown 5Y
-97.7%
Peak to trough
ATR 14
0.43
8.86% of price
Beta (reported)
1.49
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Verrica Pharmaceuticals Q2 Earnings Call Highlights
MarketBeat · 15d ago
Verrica Pharmaceuticals Inc. (VRCA) Reports Q2 Loss, Beats Revenue Estimates
Zacks · 16d ago
Verrica Pharmaceuticals Reports Second Quarter 2026 Financial Results
GlobeNewswire · 16d ago
Verrica Pharmaceuticals Closes Credit Facility For Up To $27.5 Million in Non-Dilutive Growth Capital
GlobeNewswire · 16d ago
Verrica Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026
GlobeNewswire · 23d ago
Verrica Pharmaceuticals Signs Distribution Deal With Medomie for Molluscum Treatment
MT Newswires · 32d ago
Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel
GlobeNewswire · 32d ago
Verrica Pharmaceuticals' Doses First US Patient in Phase 3 Trial Evaluating Ycanth to Treat Common Warts
MT Newswires · 61d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.